A recent study tracked 1.7 million Americans with Type 2 diabetes, revealing that those taking semaglutide, the active ingredient in Ozempic, have a 40% to 70% lower risk of developing Alzheimer's-related dementia compared to those on other diabetes medications. The study found that semaglutide significantly reduces the risk of overall Alzheimer's disease-related dementia incidence, showing strong protective effects against vascular dementia. However, its effects on other dementia types, like frontotemporal dementia, were less notable. Researchers suggest that semaglutide may help reduce inflammation and assist in clearing toxic proteins linked to neurodegeneration. Despite these promising findings, experts urge caution, noting that the study is observational, and clinical trials are necessary to confirm these connections. Side effects common to semaglutide include nausea, vomiting, and diarrhea. The results provide hope for a potential intervention for the 55 million individuals living with dementia worldwide, although it should not yet be seen as a dementia prevention drug.

Source đź”—